Emalex eyes FDA approval for Tourette syndrome therapy after Phase III success
The Phase III DIAMOND trial met both its primary and secondary endpoints of reducing tics in both children and adult patients ...
BioSpace2d
Emalex Heads to FDA After Phase III Tourette Syndrome Win
In the Phase III trial, 41.9% of pediatric Tourette syndrome patients relapsed after ecopipam treatment, as compared with ...
Crain's Chicago Business2d
Chicago pharma gets good news on Tourette syndrome drug candidate
Ecopipam showed statistical significance in treating Tourette syndrome versus a placebo for both its primary efficacy ...
FierceBiotech3d
Emalex dopamine blocker stops Tourette syndrome relapse in phase 3 win
Emalex Biosciences’ dopamine blocker led to fewer patients with Tourette syndrome relapsing in a phase 3 trial, setting the ...
Pharm Exec1d
Ecopipam Demonstrates Promise in Patients with Tourette Syndrome
Results from a Phase III registrational study suggest that ecopipam has potential as a first-in-class dopamine-1 receptor ...
The Pharma Letter2d
Emalex Biosciences’ lead candidate Phase III win in Tourette syndrome
Chicago, USA-based Emalex Biosciences announced positive top-line data from its Phase III registrational study of ecopipam, a ...
Emalex Biosciences’ Lead Candidate Meets Primary and Secondary Endpoints in Phase 3 Tourette Syndrome Study
Emalex Biosciences met primary and secondary endpoints in its Phase 3 registrational trial of ecopipam for patients with ...
Monthly Prescribing Reference3d
Novel Dopamine-1 Receptor Antagonist Shows Promise for Tourette Syndrome
“These results strengthen our confidence in ecopipam as a potential first-in-class treatment for patients with Tourette syndrome,” said Frederick Munschauer, MD, Emalex Biosciences chief ...
ENDPOINTS NEWS3d
Chica­go biotech Emalex says it cleared a Phase 3 for Tourette syn­drome, will seek FDA ap­proval
Emalex Biosciences said its daily oral tablet helped reduce relapses for children and adults with Tourette syndrome in a ...
Morningstar3d
Emalex Biosciences’ Lead Candidate Meets Primary and Secondary Endpoints in Phase 3 Tourette Syndrome Study
“These results strengthen our confidence in ecopipam as a potential first-in-class treatment for patients with Tourette syndrome,” said Frederick Munschauer, MD, Emalex Biosciences chief ...